Results 181 to 190 of about 106,112 (301)

Synovial Fluid Cell Counts and the Degree of Synovial Tissue Lymphocytic Inflammation in Patients with Rheumatoid Arthritis

ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Objective The synovial tissue pathotype may determine the treatment response in rheumatoid arthritis (RA); however, biopsies are not widely available. Synovial fluid is a promising tissue surrogate. Our purpose was to compare RA synovial fluid cell counts with histopathology and use synovial fluid to predict tissue inflammation.
Susan M. Goodman, Michael Parides, Solana Cushing, Daniel Ramirez, Edward DiCarlo, Kristine Carandang, Renée A. Davis, Rebecca B. Blank, Laura T. Donlin, Anna Helena Jonsson, Amit Lakhanpal, Bella Mehta, Dana Orange, Melanie H. Smith   +13 more
wiley   +1 more source

A Pilot Study on Tocilizumab in Very-Late-Onset Myasthenia Gravis

, 2023
Tingting Yang, Zeyi Wang, Ze-Xin Fan, Bo-Yi Yuan, Lin Ma, Jianfeng Lü, Pen-Ju Liu, Yang He, Guang-Zhi Liu   +8 more
openalex   +2 more sources

Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report [PDF]

, 2023
Paula Kilić, Lucija Ikić, Miroslav Mayer, Marinko Artuković, Ksenija Maštrović Radončić, Marina Ikić Matijašević   +5 more
openalex   +1 more source

Basophil Activation Test for the In Vitro Diagnosis of Tocilizumab Hypersensitivity

Clinical &Experimental Allergy, EarlyView.
Ana Koren, Luka Dejanović, Peter Korošec, Peter Kopač   +3 more
wiley   +1 more source

Clinical Characteristics and Evolution of Interstitial Lung Disease in Subtypes of Idiopathic Inflammatory Myositis With Prevalent Lung Manifestation: A Retrospective Analysis

ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Objective Interstitial lung disease (ILD) is common in idiopathic inflammatory myositis (IIM), particularly in antisynthetase syndrome (ASyS), antimelanoma differentiation‐associated protein 5 (anti‐MDA5) syndrome, and scleromyositis. ILD can progress despite resolution of extrapulmonary symptoms, termed postmyopathic progressive pulmonary fibrosis ...
Julia Clark, Dora Chan, Damon Dhillon, Jan Dutz, Gillian Goobie, Kun Huang   +5 more
wiley   +1 more source

Tocilizumab as an effective treatment option for idiopathic orbital inflammation: a case report and literature review. [PDF]

Int J Ophthalmol
Zhang HY, Zhang HJ, Zhou HF.
europepmc   +1 more source

A Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery

Advanced Science, Volume 13, Issue 7, 3 February 2026.
This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang, Chaohu Wang, Jun Fan, Zexin Chen, Haoying Yu, Yawen Bai, Tingcheng Zhang, Qianchao Zhu, Yiwen Feng, Peirong Niu, Jiaqian Chen, Liping Yang, Xueying Li, Lei Yu, Songtao Qi, Yi Liu   +15 more
wiley   +1 more source

<p>Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study</p>

, 2020
Marco A. Cimmino, M. Parodi, Francesca Barbieri, Stefano Bombardieri, G. Zampogna, Annamaria Iagnocco, Alberto Batticciotto, Luca Maria Sconfienza, L. Sinigaglia, Fabrizio De Benedetti, Fabiola Atzeni, Piercarlo Sarzi‐Puttini   +11 more
openalex   +2 more sources

Impact of tocilizumab administration on mortality in severe COVID-19 [PDF]

, 2020
Andrew Tsai, Oumou Diawara, Ronald Nahass, Luigi Brunetti   +3 more
openalex   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source